InFlectis BioScience IFB-088 enters phase 1 Clinical Trial
Nantes, France – May 22th, 2018. InFlectis BioScience SAS, a drug discovery company committed to the development of innovative therapeutics harnessing the Integrated Stress Response for the treatment...
View ArticleReport on the 11th Neuromuscular Translational Research Conference in April 2018
More than 200 delegates from around the world attended the conference held on 19th and 20th April in Fitzwilliam College, Cambridge and hosted by the MRC Centre for Neuromuscular Diseases and Muscular...
View ArticleAwareness Month Coverage 2018
Awareness Month has gone extremely well, kicking off with our trustee, Paul Fleming being on Sky News Sunrise on 1st Septembe. You can watch this great interview at...
View ArticleImplanting Stem-derived Schwann Cells Improves Motor Activity, Nerve...
Implanting stem-derived Schwann-like cells into mice with Charcot-Marie-Tooth type 1A improved neuron function, leading to better motor activity and nerve regeneration, according to new research from...
View ArticleCMT&Me App to be launched this month!
Would you download an app to participate in a survey that promises to collect rich demographic and epidemiological data about all stages of CMT and its treatment, as well as quality of life? The...
View ArticleHELP, MY FEET ARE SHRINKING! Lawyer raises awareness for CMT disease that’s...
Symptoms of stumbling and balance problems led to people accusing the 29-year-old lawyer of being drunk. The post HELP, MY FEET ARE SHRINKING! Lawyer raises awareness for CMT disease that’s seen her...
View ArticleUnderstanding cell membrane changes
Dr Andrew Shevchuk and his team from Imperial College London will investigate how mutations associated with some types of centronuclear myopathy and Charcot-Marie-Tooth disease (CMT) The post...
View ArticleNew therapeutic targets identified in Charcot-Marie-Tooth disease
Research conducted at the Institute of Neurology of University College London (UCL) just published in the Proceedings of the National Academy of Sciences USA has identified a set of novel therapeutic...
View ArticleAcceleron Announces Plans to Initiate a Phase 2 Trial of ACE-083
Acceleron Pharma Inc, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics The post Acceleron Announces Plans to Initiate a...
View Article“My daughter was in a wheelchair just nine months after being diagnosed with...
A mum wants to raise awareness of a rare condition that saw her daughter in a wheelchair just nine months after she was diagnosed. The post “My daughter was in a wheelchair just nine months after being...
View ArticleMuscular Dystrophy UK launches new course for Teachers
Muscular Dystrophy UK has announced the launch of a new online course for teaching and education staff working with secondary school children with a muscle-wasting condition The post Muscular Dystrophy...
View ArticleCMT Awareness Month will be October from 2019
This brings us inline with the European CMT Federation of which we are a founding member organisation. It is prevents clashes with other larger charities and their awareness month! The post CMT...
View ArticleInFlectis BioScience announces favorable results for IFB-088 Phase 1 Single...
Nantes, France – May 15th, 2019 InFlectis BioScience SAS, a drug discovery company committed to the development of innovative therapeutics harnessing the Integrated Stress Response for the treatment of...
View ArticlePress Release – Inside Information Pharnext Provides U.S. Regulatory Update...
2019.08.30_PXT3003_US_FDA_EN The post Press Release – Inside Information Pharnext Provides U.S. Regulatory Update on PLEODRUG™ appeared first on Charcot-Marie-Tooth UK.
View ArticleCRISPR/Cas9 Treatment Can Improve Nerve Functioning in Mouse Model of CMT1A,...
CRISPR/Cas9 Treatment Can Improve Nerve Functioning in Mouse Model of CMT1A, Study Suggests The post CRISPR/Cas9 Treatment Can Improve Nerve Functioning in Mouse Model of CMT1A, Study Suggests appeared...
View ArticlePharnext Announces Encouraging Data from Open ‐ Label Phase 3 Extension Study...
Pharnext Announces Encouraging Data from Open ‐ Label Phase 3 Extension Study of PXT3003 The post Pharnext Announces Encouraging Data from Open ‐ Label Phase 3 Extension Study of PXT3003 appeared first...
View ArticleRare Film Festival 2020
The first ever Rare Film Festival took place on 10th February at the Regent Street Cinema Over 50 films were entered into the festival including the CMT United Kingdom entry which you can vote for here...
View ArticleCoronavirus – COVID-19
Below is some guidance around the risks of coronavirus and what you can do to stay safe. For the up to date current advice visit the NHS website (updated 18th March 2020) There are no specific...
View ArticleClik here to view.
Pharnext Announces PXT3003 for the Treatment of Charcot-Marie-Tooth Disease...
Press Release Pharnext Announces PXT3003 for the Treatment of CharcotMarie-Tooth Disease Type 1A has Been Granted Promising Innovative Medicine (PIM) Designation by UK Medicines and Healthcare...
View Article